Related Experiment Videos
[New therapy options in colorectal carcinoma]
1Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus, Dresden. Gunnar.Folprecht@uniklinikum-dresden.de
Therapeutische Umschau. Revue Therapeutique
|July 16, 2004
Summary
New chemotherapy combinations and targeted therapies like bevacizumab significantly improve treatment outcomes for metastatic colorectal cancer patients. These advancements increase response rates and prolong overall survival, offering new hope for effective management.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Colorectal cancer treatment has advanced with new chemotherapeutic agents.
- Combination therapies are crucial for managing metastatic colorectal cancer (mCRC).
Purpose of the Study:
- To review current chemotherapeutic options for mCRC.
- To evaluate the efficacy of novel agents, including monoclonal antibodies.
Main Methods:
- Analysis of combination chemotherapy regimens (irinotecan/oxaliplatin with 5-FU/folinic acid).
- Assessment of oral 5-FU prodrugs (capecitabine) efficacy.
- Review of studies on monoclonal antibodies (bevacizumab, cetuximab).
Main Results:
- Combination therapy yields response rates of approximately 50% and extends median survival to 20 months.
- Bevacizumab (VEGF-antibody) prolongs survival by over 4 months compared to chemotherapy alone.
- Cetuximab (EGF-receptor antibody) shows efficacy in patients progressing on irinotecan.
Conclusions:
- Chemotherapy combinations and targeted therapies represent significant progress in mCRC treatment.
- Monoclonal antibodies offer survival benefits and new therapeutic strategies for mCRC.